AKT1 and neoplasm: A recent advance uses a small molecule cocktail (SMC) such as SB431542 (TGF-β inhibitor), CHIR99021 (GSK3β inhibitor), and BIX01294 (G9a histone methyltransferase inhibitor), to epigenetically reprogram drug-resistant cells toward hepatocyte-like differentiation, causing tumor regression via AKT/mTOR/HIF1α modulation (642).